US FDA Certifies Merck’s Treatment For An Uncommon Lung Ailment
Approval of Merck’s treatment for individuals with high blood pressure brought on by pulmonary artery constriction was approved by the U.S. Food and Drug Administration, giving the multinational pharmaceutical company access to yet another potentially game-changing medication. Merck’s stock rose more than 4% during extended trading. About 40,000 Americans suffer with pulmonary arterial hypertension (PAH), which…









